Report cover image

Erythema Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Feb 06, 2024
Length 180 Pages
SKU # EMAR18558233

Description

Erythema Market Report and Forecast 2024-2032


Erythema Market Report and Forecast 2024-2032

Erythema Market Outlook

The erythema market size was valued at USD 178.9 million in 2023, driven by growing use of advanced imaging technologies in the 7 major markets. The market size is anticipated to grow at a CAGR of 5.80% during the forecast period of 2024-2032 to achieve a value of USD 297.7 million by 2032.

Erythema: Introduction

Erythema is a common skin condition characterized by redness or rash, resulting from increased blood flow in superficial capillaries. It can occur due to various factors, including sun exposure, insect bites, allergic reactions, or underlying medical conditions like infections or autoimmune diseases. Erythema manifests as a flat or raised red area, often accompanied by warmth and sometimes itching or pain. Treatment focuses on addressing the underlying cause and may include medications, creams, or lifestyle adjustments to alleviate symptoms.

Key Trends in the Erythema Market

There's a growing use of advanced imaging technologies, like dermoscopy and confocal microscopy, for precise diagnosis of erythema and its underlying causes. Laser therapies and phototherapy are also gaining popularity in treatment, offering non-invasive solutions with promising results.

As understanding of the molecular mechanisms behind various skin conditions, including erythema, improves, there is a trend toward personalized treatment approaches. Biologic drugs and targeted therapies are being developed to address specific pathways involved in skin inflammation and erythema, providing more effective and tailored treatment options.

With the rise of digital health platforms and social media, there's increased consumer awareness about skin health and conditions like erythema. This trend is driving the demand for over-the-counter products and self-care solutions, including skincare products with anti-inflammatory properties and sunscreens to prevent erythema from UV exposure.

Consumers are increasingly seeking natural and organic skincare products, perceiving them as safer and gentler on the skin. This trend is influencing the market, with many companies expanding their product lines to include natural ingredients known for their soothing and anti-inflammatory properties.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers is key in driving innovation in the erythema market. Ongoing research into the pathophysiology of erythema and associated conditions is crucial for developing new and effective treatment options.

Erythema Market Segmentation

Market Breakup by Type
  • Erythema Multiforme
  • Erythema Nodosum
  • Erythema Ab Igne
  • Erythema Chronicum Migrans
  • Erythema Induratum
  • Erythema Infectiosum
  • Erythema Marginatum
  • Erythema Toxicum
  • Erythema Gyratum Repens
  • Palmar Erythema
  • Erythema Annulare Centrifugum
Market Breakup by Drug Class
  • Antibiotics
  • Antihistamines
  • Analgesics
  • NSAIDs
  • Corticosteroid
  • Antiviral
  • Antifungal
  • Antibacterial
Market Breakup by Route of Administration
  • Oral
  • Topical
  • Intravenous
  • Others
Market Breakup by End User
  • Hospital and Clinics
  • Ambulatory Clinics
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Erythema Market Overview

In North America, the erythema market is influenced by a high prevalence of skin conditions and a strong focus on dermatological health. The market is advanced, with a wide range of treatment options including topical agents, systemic medications, and innovative therapies like biologics for chronic or severe cases. There's also a growing trend towards personalized dermatological care and the use of telemedicine for diagnosis and treatment. Awareness campaigns and patient education about skin health and sun protection are significant market drivers.

Europe's market benefits from comprehensive healthcare systems and strict regulatory standards for dermatological products. There's a strong emphasis on research and development, leading to the availability of advanced treatment options for erythema and related skin conditions. Public health initiatives promote awareness about skin health, including the importance of sun protection to prevent erythema. The market also sees a trend towards natural and organic skincare products, reflecting the broader shift towards sustainability and health-conscious choices in the region.

Japan's market for erythema is characterized by a high standard of healthcare and a culture that places a strong emphasis on skin appearance and health. The country is known for its innovative skincare and dermatological treatments, including cutting-edge technologies and cosmetic procedures. There's also a significant market for skincare products aimed at preventing and treating erythema, especially sun-induced erythema, in line with the country's high awareness of sun protection and skin care.

Erythema Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • GSK plc. (U.S.)
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Astrazeneca
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Abbvie
  • Amgen Inc.
  • AB Sciences
  • Eisai Co., Ltd
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Valeant Pharmaceuticals International Inc.
  • Bausch Health Companies Inc.
  • Enzon Pharmaceuticals
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

180 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Erythema Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Erythema Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Erythema Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Erythema Epidemiology Forecast (2017-2032)
5.3.1 Germany Erythema Epidemiology Forecast (2017-2032)
5.3.2 France Erythema Epidemiology Forecast (2017-2032)
5.3.3 Italy Erythema Epidemiology Forecast (2017-2032)
5.3.4 Spain Erythema Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Erythema Epidemiology Forecast (2017-2032)
5.4 Japan Erythema Epidemiology Forecast (2017-2032)
6 Erythema Market Overview – 7MM
6.1 Erythema Market Historical Value (2017-2023)
6.2 Erythema Market Forecast Value (2024-2032)
7 Erythema Market Landscape – 7MM
7.1 Erythema: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Erythema Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Drug Class
8 Erythema Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Erythema Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Erythema Market Segmentation – 7MM
11.1 Erythema Market by Type
11.1.1 Market Overview
11.1.2 Erythema Multiforme
11.1.3 Erythema Nodosum
11.1.4 Erythema Ab Igne
11.1.5 Erythema Chronicum Migrans
11.1.6 Erythema Induratum
11.1.7 Erythema Infectiosum
11.1.8 Erythema Marginatum
11.1.9 Erythema Toxicum
11.1.10 Erythema Gyratum Repens
11.1.11 Palmar Erythema
11.1.12 Erythema Annulare Centrifugum
11.2 Erythema Market by Drug Class
11.2.1 Market Overview
11.2.2 Antibiotics
11.2.3 Antihistamines
11.2.4 Analgesics
11.2.5 NSAIDs
11.2.6 Corticosteroid
11.2.7 Antiviral
11.2.8 Antifungal
11.2.9 Antibacterial
11.3 Erythema Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Topical
11.3.4 Intravenous
11.3.5 Others
11.4 Erythema Market by End User
11.4.1 Market Overview
11.4.2 Hospital and Clinics
11.4.3 Ambulatory Clinics
11.4.4 Others
11.5 Erythema Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.4 Japan
12 United States Erythema Market
12.1 Erythema Market Historical Value (2017-2023)
12.2 Erythema Market Forecast Value (2024-2032)
12.2.1 Erythema Market by Disease Type
12.2.2 Erythema Market by Drug Class
13 EU-4 and United Kingdom Erythema Market
13.1 Erythema Market Historical Value (2017-2023)
13.2 Erythema Market Forecast Value (2024-2032)
13.3 Germany Erythema Market Overview
13.3.1 Erythema Market by Disease Type
13.3.2 Erythema Market by Drug Class
13.4 France Erythema Market Overview
13.4.1 Erythema Market by Disease Type
13.4.2 Erythema Market by Drug Class
13.5 Italy Erythema Market Overview
13.5.1 Erythema Market by Disease Type
13.5.2 Erythema Market by Drug Class
13.6 Spain Erythema Market Overview
13.6.1 Erythema Market by Disease Type
13.6.2 Erythema Market by Drug Class
13.7 United Kingdom Erythema Market Overview
13.7.1 Erythema Market by Disease Type
13.7.2 Erythema Market by Drug Class
14 Japan Erythema Market
14.1 Erythema Market Historical Value (2017-2023)
14.2 Erythema Market Forecast Value (2024-2032)
14.2.1 Erythema Market by Disease Type
14.2.2 Erythema Market by Drug Class
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 GSK plc. (U.S.)
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 F. Hoffmann-La Roche Ltd
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Novartis AG
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Astrazeneca
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Pfizer Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Bristol-Myers Squibb Company
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Abbvie
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Amgen Inc.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 AB Sciences
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Eisai Co., Ltd
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Regeneron Pharmaceuticals Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Sanofi S.A.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Valeant Pharmaceuticals International Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Bausch Health Companies Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Enzon Pharmaceuticals
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Erythema Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us